Related Experiment Videos
Follow-up of 151 patients with high-titer U1RNP antibodies
P B Frandsen1, N J Kriegbaum, S Ullman
1Department of Nephrology, Hvidovre University Hospital, Denmark.
Insights
High-titer anti-U1RNP antibodies in patients often indicate evolving connective tissue disease (CTD). Many initially undiagnosed patients developed specific CTD diagnoses like mixed connective tissue disease (MCTD) over time.
Area of Science:
- Rheumatology
- Immunology
- Clinical Medicine
Background:
- High-titer antibodies against U1 ribonucleoprotein (anti-U1RNP) are associated with connective tissue diseases (CTDs).
- Understanding the clinical evolution of CTDs in patients with anti-U1RNP antibodies is crucial for diagnosis and management.
Purpose of the Study:
- To analyze the longitudinal clinical course and diagnostic transitions in patients with high-titer anti-U1RNP antibodies.
- To assess the stability of mixed connective tissue disease (MCTD) diagnoses in this patient cohort.
Main Methods:
- Longitudinal follow-up study of 151 patients with high-titer anti-U1RNP antibodies.
- Clinical findings were monitored, and formal connective tissue disease (CTD) diagnoses were assigned over a mean follow-up of 7.1 years.
Main Results:
- Of 84 patients initially presenting with undifferentiated CTD, a significant proportion developed defined CTDs, most commonly MCTD.
- By the end of the follow-up, 127 patients had developed a well-defined CTD, with MCTD being the most frequent final diagnosis (n=97).
Conclusions:
- Connective tissue disease associated with high-titer anti-U1RNP antibodies can be dynamic and sequential.
- Established diagnostic criteria for MCTD appear to identify a clinically stable subgroup within this broader patient population.
Abstract:
We performed a longitudinal follow-up study of clinical findings in 151 patients with high-titer antibodies against U1 ribonucleoprotein (U1RNP) as measured by haemagglutination. Formal connective tissue disease (CTD) diagnoses were assigned and diagnostic transitions analysed. One-hundred eighteen females and 33 males entered the study; the mean duration of follow-up was 7.1 years. Mean age at entry was 34.7 years; 73% of the patients had early disease (duration < 2 years). Fifty-six patients (37%) presented with a definite diagnosis, most often mixed connective tissue disease (MCTD, n = 40), followed by systemic lupus erythematosus (SLE, n = 11) and systemic sclerosis (SSc, n = 5). Of 84 patients (56%) presenting with nonspecific symptoms of possible, "undifferentiated" CTD, 58 developed MCTD, 4 SSc and 2 SLE. By the end of the follow-up period. 127 patients had developed a well-defined CTD; final diagnoses were: MCTD (n = 97), SLE (n = 18), SSc (n = 12). We conclude that CTD in the context of high-titer anti-U1RNP antibodies may be transitive and sequential in nature, although the diagnostic criteria for MCTD previously proposed by our group seem to delimit a clinically stable condition in most patients in this subgroup.